RxDoctor Payments Data

Billy Evans, MD

Family Medicine · Glendale, AZNPI 1114942422

Payments from drug & device makers

$1,586in general payments, 2019–2025

Across 51 payments — averaging $31.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$282
  • Novo Nordisk$270
  • Biohaven Pharmaceutical Holding Company Ltd.$125
  • Johnson & Johnson$124
  • Pfizer$121
  • Corcept Therapeutics$90
  • plus $574 from 14 others

What the payments were for

  • Food & beverage$1,586100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,586 in reported general payments places this provider in the 75th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$83,415
Medicare patients
174
Services billed
1,080

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide91$155,278
FarxigaDapagliflozin Propanediol45$63,733
EliquisApixaban48$55,210
TrulicityDulaglutide26$49,741
JardianceEmpagliflozin26$45,340
LinzessLinaclotide40$32,024
JanuviaSitagliptin Phosphate25$31,961
Tresiba Flextouch U-100Insulin Degludec20$24,920
MounjaroTirzepatide16$21,213
Breo ElliptaFluticasone/Vilanterol22$14,171
XareltoRivaroxaban11$12,485
Spiriva HandihalerTiotropium Bromide14$11,940
JanumetSitagliptin Phos/Metformin Hcl23$11,642
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$6,812
Gabapentin249$5,772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$270$155,27891 claims
Lilly USA, LLCTrulicity, Mounjaro$57$70,95442 claims
AstraZenecaFarxiga, Symbicort$282$69,00856 claims
PfizerEliquis$121$55,21048 claims
AbbVieLinzess$42$32,02440 claims
GSKBreo Ellipta$52$14,17122 claims
Johnson & JohnsonXarelto$124$12,48511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →